Melanoma and intellectual disability: do prognostic factors at diagnosis differ from general population?

Autor: Lesage C; Department of Dermatology, University Hospital, Montpellier, France., Habib-Hadef S; ONCODEFI, Montpellier, France., Trétarre B; Registre des Tumeurs de l'Hérault, Montpellier, France., Lesage FX; Department of Professional pathologies, University of Montpellier, University Hospital Montpellier, Montpellier, France., Bessaoud F, Varey E; Réseau pour la Recherche et l'Investigation Clinique sur le Mélanome, Nantes University Hospital, Nantes, France., Guillot B; Department of Dermatology, University Hospital, Montpellier, France., Satgé D; ONCODEFI, Montpellier, France.; Institut Desbrest d'Epidémiologie et de Santé Publique, IDESP UMR UA11 INSERM Univ. Montpellier, Montpellier, France.
Jazyk: angličtina
Zdroj: Journal of intellectual disability research : JIDR [J Intellect Disabil Res] 2022 Apr; Vol. 66 (4), pp. 392-398. Date of Electronic Publication: 2022 Feb 08.
DOI: 10.1111/jir.12915
Abstrakt: Background: Few melanoma cases are reported in individuals with intellectual disability (ID), and prognostic factors at diagnosis are unknown in this population. This work was designed to investigate whether prognostic factors at diagnostic are different in patients with ID compared with a general population.
Methods: Melanoma cases retrieved from Hérault's Tumour Registry (HTR) from 1995 to 2015 were cross-referenced against a list of adult patients with ID, living in Hérault. Major prognostic factors were compared with those in non-ID melanoma patients included in HTR and in patients followed by Montpellier University Hospital and included in the Réseau pour la Recherche et l'Investigation Clinique sur le Mélanome (RIC-Mel) database.
Results: Ten melanoma cases in individuals with ID were identified and compared with 3804 non-ID melanoma cases in HTR and 1024 non-ID melanoma cases included in RIC-Mel. Mean Breslow thickness at diagnosis was 4.6 mm in melanoma cases among those with ID versus 1.89 mm in HTR (P = 0.109) and 2.36 mm in RIC-Mel (P = 0.156). Stage at diagnosis was superior to stage IIB in 42.9% of ID cases versus 11.4% of non-ID cases in HTR (P < 0.05) and 8.5% in RIC-Mel (P < 0.05).
Conclusions: Melanomas in patients with ID had less favourable prognostic factors at diagnosis, including higher Breslow thickness and more advanced stage, than melanomas in non-ID patients. These adverse prognostic factors indicate a later diagnosis in this population, leading to a poorer prognosis. This work underlines the need to improve melanoma screening among individuals with ID.
(© 2022 MENCAP and International Association of the Scientific Study of Intellectual and Developmental Disabilities and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje